Elite Pharmaceuticals, Inc. Names Marc Bregman as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / April 29, 2021 / Elite Pharmaceuticals, Inc. ( Elite or the Company ) (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, announced today that Marc Bregman, CPA, has been appointed as Chief Financial Officer (CFO), effective May 17, 2021. Mr. Bregman and will report to Elite s President and CEO, Nasrat Hakim.
Mr. Bregman has more than 27 years of financial and operational experience, including positions as Controller at Langan Engineering & Environmental Services and Controller at Chemtrade Logistics. He held corporate financial positions at Chemetall and National Starch & Chemical Company and was a supervisor and senior auditor at Ernst & Young. Mr. Bregman brings experience in financial accounting, financial planning & analysis, governance & compliance, financial auditing, Sarbanes-Oxley Act (SOX) compliance, and cost accountin
Elite Pharmaceuticals, Inc Names Marc Bregman as Chief Financial Officer
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
ADVERTISEMENT
DOJ Wants More Info On Morgan Lewis Glenmark, Teva Work
Law360 (April 26, 2021, 7:12 PM EDT) The U.S. Department of Justice told a Pennsylvania federal judge on Friday that Morgan Lewis & Bockius LLP must elaborate on an ethical wall that the firm says prevents conflicts of interests if it wants to keep defending Glenmark in a criminal price-fixing case against it and Teva.
Prosecutors urged U.S. District Judge R. Barclay Surrick to require Morgan Lewis to answer a series of questions about its ability to ethically represent Glenmark Pharmaceuticals Inc. USA in the generic-drug price-fixing case. The department has taken issue with the firm s prior representation of fellow defendant Teva Pharmaceutical Industries Ltd. in the criminal.
ADVERTISEMENT
ADVERTISEMENT
Glenmark Rips DOJ s Misplaced Morgan Lewis Conflict Claim
Law360 (March 15, 2021, 10:27 PM EDT) Glenmark blasted the U.S. Department of Justice Friday for raising concerns about Morgan Lewis & Bockius LLP s potential conflicts of interest in representing the generics drugmaker in its fight against criminal price-fixing charges, arguing that the government s concerns are misplaced and the law firm has nothing to hide.
In a 16-page response brief, Glenmark Pharmaceuticals Inc. USA argued that although Morgan Lewis represents both Glenmark and Teva in civil litigation and has represented them both briefly in the criminal case, Teva is a sophisticated party with experienced attorneys who have agreed to let Morgan Lewis drop Teva as a client, waiving.
(MENAFN - America News Hour) Market Forecast
The Global Immunosuppressive Drugs Market is expected to cross USD 1.39 Billion by 2025 at a CAGR of 4.63%. Immunosuppressants are generally used post organ transplants and for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. According to the World Health Organization (WHO) and the Spanish Transplant Organization, Organización Nacional de Trasplantes (ONT), in 2018, organ transplants increased by 7.25% from the previous year to reach approximately 138,000, including 40.4% living kidney transplants and 19.8% living liver transplants.
Download Sample of This Strategic Report-
Market Synopsis
Immunosuppressive drugs find utility post organ transplants when the receiver s immunity must be suppressed for the body to accept the newly attached organ.This market is growing due to the increasing number of organ transplants and advances in tissue engineering and organ transplant techniques
vimarsana © 2020. All Rights Reserved.